![Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials | Clinical Cancer Research Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials | Clinical Cancer Research](https://clincancerres.aacrjournals.org/sites/default/files/highwire/clincanres/24/10.cover-source.jpg)
Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials | Clinical Cancer Research
![Response rates Overall response rate and depth of response according to... | Download Scientific Diagram Response rates Overall response rate and depth of response according to... | Download Scientific Diagram](https://www.researchgate.net/publication/341590087/figure/fig3/AS:958461890281480@1605526530128/Response-rates-Overall-response-rate-and-depth-of-response-according-to-renal-function-in.png)
Response rates Overall response rate and depth of response according to... | Download Scientific Diagram
PLOS ONE: Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis
![ESMO 2021: A Phase 2 Prospective Trial of Frontline Cabozantinib in Metastatic Collecting Duct Renal Cell Carcinoma: The BONSAI Trial ESMO 2021: A Phase 2 Prospective Trial of Frontline Cabozantinib in Metastatic Collecting Duct Renal Cell Carcinoma: The BONSAI Trial](https://www.urotoday.com/images/com-doc-importer/18-esmo-2021/esmo-2021-a-phase-2-prospective-trial-of-frontline-cabozantinib-in-metastatic-collecting-duct-renal-cell-carcinoma-the-bonsai-trial-meeturo-2-1/image-0.jpg)
ESMO 2021: A Phase 2 Prospective Trial of Frontline Cabozantinib in Metastatic Collecting Duct Renal Cell Carcinoma: The BONSAI Trial
![Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer | Full Text Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40425-017-0276-8/MediaObjects/40425_2017_276_Fig1_HTML.gif)
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer | Full Text
![Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials | Clinical Cancer Research Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials | Clinical Cancer Research](https://clincancerres.aacrjournals.org/content/clincanres/24/10/2268/F1.large.jpg)
Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials | Clinical Cancer Research
![Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials | Clinical Cancer Research Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials | Clinical Cancer Research](https://clincancerres.aacrjournals.org/content/clincanres/24/10/2268/F2.large.jpg)